These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 22343622)

  • 1. The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models.
    Holt SV; Logié A; Odedra R; Heier A; Heaton SP; Alferez D; Davies BR; Wilkinson RW; Smith PD
    Br J Cancer; 2012 Feb; 106(5):858-66. PubMed ID: 22343622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MEK1/2 inhibitor selumetinib (AZD6244) inhibits growth of ovarian clear cell carcinoma in a PEA-15-dependent manner in a mouse xenograft model.
    Bartholomeusz C; Oishi T; Saso H; Akar U; Liu P; Kondo K; Kazansky A; Krishnamurthy S; Lee J; Esteva FJ; Kigawa J; Ueno NT
    Mol Cancer Ther; 2012 Feb; 11(2):360-9. PubMed ID: 22144664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute tumour response to the MEK1/2 inhibitor selumetinib (AZD6244, ARRY-142886) evaluated by non-invasive diffusion-weighted MRI.
    Beloueche-Babari M; Jamin Y; Arunan V; Walker-Samuel S; Revill M; Smith PD; Halliday J; Waterton JC; Barjat H; Workman P; Leach MO; Robinson SP
    Br J Cancer; 2013 Sep; 109(6):1562-9. PubMed ID: 23942066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
    Takahashi O; Komaki R; Smith PD; Jürgensmeier JM; Ryan A; Bekele BN; Wistuba II; Jacoby JJ; Korshunova MV; Biernacka A; Erez B; Hosho K; Herbst RS; O'Reilly MS
    Clin Cancer Res; 2012 Mar; 18(6):1641-54. PubMed ID: 22275507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selumetinib in the treatment of non-small-cell lung cancer.
    Bernabé R; Patrao A; Carter L; Blackhall F; Dean E
    Future Oncol; 2016 Nov; 12(22):2545-2560. PubMed ID: 27467210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors.
    LoRusso PM; Infante JR; Kim KB; Burris HA; Curt G; Emeribe U; Clemett D; Tomkinson HK; Cohen RB
    BMC Cancer; 2017 Mar; 17(1):173. PubMed ID: 28264648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
    Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.
    Haass NK; Sproesser K; Nguyen TK; Contractor R; Medina CA; Nathanson KL; Herlyn M; Smalley KS
    Clin Cancer Res; 2008 Jan; 14(1):230-9. PubMed ID: 18172275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.
    Flanigan SA; Pitts TM; Newton TP; Kulikowski GN; Tan AC; McManus MC; Spreafico A; Kachaeva MI; Selby HM; Tentler JJ; Eckhardt SG; Leong S
    Clin Cancer Res; 2013 Nov; 19(22):6219-29. PubMed ID: 24045180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BH3 mimetic ABT-263 synergizes with the MEK1/2 inhibitor selumetinib/AZD6244 to promote BIM-dependent tumour cell death and inhibit acquired resistance.
    Sale MJ; Cook SJ
    Biochem J; 2013 Mar; 450(2):285-94. PubMed ID: 23234544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma.
    Kirkwood JM; Bastholt L; Robert C; Sosman J; Larkin J; Hersey P; Middleton M; Cantarini M; Zazulina V; Kemsley K; Dummer R
    Clin Cancer Res; 2012 Jan; 18(2):555-67. PubMed ID: 22048237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treating non-small cell lung cancer with selumetinib: an up-to-date drug evaluation.
    Imyanitov EN; Levchenko EV; Kuligina ES; Orlov SV
    Expert Opin Pharmacother; 2020 Nov; 21(16):1943-1953. PubMed ID: 32880495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the mitogen‑activated protein kinase kinase and protein kinase A pathways overcomes acquired resistance to Selumetinib in low‑grade glioma cells.
    Melotti L; Meco D; Battaglia A; Buzzonetti A; Martini M; Ruggiero A; Scambia G; Riccardi R
    Oncol Rep; 2021 Feb; 45(2):752-763. PubMed ID: 33416182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
    Ma BB; Lui VW; Cheung CS; Lau CP; Ho K; Hui EP; Tsui SK; Ng MH; Cheng SH; Ng PK; Tsao SW; Chan AT
    Invest New Drugs; 2013 Feb; 31(1):30-8. PubMed ID: 22565394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MEK1/2 inhibition enhances the radiosensitivity of cancer cells by downregulating survival and growth signals mediated by EGFR ligands.
    Chung EJ; Urick ME; Kurshan N; Shield W; Asano H; Smith PD; Scroggins BS; Burkeen J; Citrin DE
    Int J Oncol; 2013 Jun; 42(6):2028-36. PubMed ID: 23588995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Study design and rationale for a randomised, placebo-controlled, double-blind study to assess the efficacy of selumetinib (AZD6244; ARRY-142886) in combination with dacarbazine in patients with metastatic uveal melanoma (SUMIT).
    Carvajal RD; Schwartz GK; Mann H; Smith I; Nathan PD
    BMC Cancer; 2015 Jun; 15():467. PubMed ID: 26059332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced apoptosis and tumor growth suppression elicited by combination of MEK (selumetinib) and mTOR kinase inhibitors (AZD8055).
    Holt SV; Logie A; Davies BR; Alferez D; Runswick S; Fenton S; Chresta CM; Gu Y; Zhang J; Wu YL; Wilkinson RW; Guichard SM; Smith PD
    Cancer Res; 2012 Apr; 72(7):1804-13. PubMed ID: 22271687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.
    Tentler JJ; Nallapareddy S; Tan AC; Spreafico A; Pitts TM; Morelli MP; Selby HM; Kachaeva MI; Flanigan SA; Kulikowski GN; Leong S; Arcaroli JJ; Messersmith WA; Eckhardt SG
    Mol Cancer Ther; 2010 Dec; 9(12):3351-62. PubMed ID: 20923857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines.
    Balmanno K; Chell SD; Gillings AS; Hayat S; Cook SJ
    Int J Cancer; 2009 Nov; 125(10):2332-41. PubMed ID: 19637312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
    Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
    Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.